Skip to main content

Table 2 Univariate logistic regression on risk of recurrence from 2011 to 2016 (n = 1362)

From: A clinical tool to predict Plasmodium vivax recurrence in Malaysia

Patient characteristic (reference)

Recurrence (n = 127)

Beta

Odds Ratio

95% CI

P-value

Age (≥ 27 years)

83

1.00

  < 27 years

44

0.62

1.90

1.14

3.17

0.00

Gender (Female)

52

1.00

 Male

75

0.92

0.40

0.28

0.58

0.00

Malaysian (Non-Malaysians)

16

1.00

 Malaysians

111

1.35

3.87

2.30

6.51

0.00

Region (Non-Western Pacific)

13

1.00

 Western Pacific

114

1.37

3.95

2.28

6.82

0.00

G6PD (Normal)

125

1.00

 Deficient

2

−1.18

0.31

0.07

1.27

0.12

Pregnant (Non-pregnant)

44

1.00

 Pregnant

8

0.89

2.44

1.05

5.66

0.04

Case locality (Urban)

0

1.00

 Rural

104

1.33

3.77

1.89

7.55

0.00

 Agriculture

23

0.70

2.01

0.84

4.77

0.11

Status of case locality (Free)

32

1.00

 Prone

0

−1.08

0.34

0.08

1.43

0.14

 Problematic

95

1.03

2.73

1.78

1.43

0.00

Disease characteristic (reference)

Length of stay (days) (range)

1–14 days

−0.01

0.99

0.95

1.04

0.68

Previous infection (no)

97

1.00

 Yes

30

−0.27

0.76

0.48

1.21

0.25

Presence of gametocyte (negative)

37

1.00

 Positive

90

0.24

1.27

0.84

1.92

0.27

Gametocyte (<80 parasite/μL)

44

1.00

  ≥ 80 parasite/μL

83

0.47

1.60

1.07

2.40

0.02

Asexual (<2700 parasite/μL)

60

1.00

  ≥ 2700 parasite/μL

67

0.068

1.07

0.74

1.54

0.71

Week onset (weeks)

1–52

0.00

1.00

0.98

1.01

0.49

Severity (Non-severe)

127

1.00

 Severe infection

0

−18.52

0.00

0.00

.

1.00

Malaria transmission type

    

 (Non-indigenous)

10

1.00

 Indigenous

107

1.21

3.35

2.06

5.50

0.00

 Relapse before

10

1.50

4.50

1.82

11.08

0.11

Treatment characteristic (reference)

Treatment type (ACT plus PQ)

106

1.00

 CP plus PQ

21

0.99

2.70

1.66

4.39

0.00

Status of treatment (Complete)

125

1.00

 Incomplete

2

1.445

4.242

0.90

20.02

0.068

  1. ACT Artemisinin-based combination therapies, WHO World Health Organization, G6PD Glucose-6-phosphate dehydrogenase, CP Chloroquine, PQ Primaquine